Pregled bibliografske jedinice broj: 1188001
Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage�IIIA)
Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage�IIIA) // Oncology Letters, 15(2) (2017), 2335-2339 doi:10.3892/ol.2017.7576 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1188001 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage�IIIA)
Autori
Bačić, Ivan ; Karlo, Robert ; Zadro, Ana ; Zadro, Zvonko ; Skitarelić, Neven ; Antabak, Anko
Izvornik
Oncology Letters (1792-1074) 15(2)
(2017);
2335-2339
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
angiogenesis ; bood vessel density ; ung cancer ; survival ; vascular endothelial growth factor-A
(angiogenesis ; blood vessel density ; lung cancer ; survival ; vascular endothelial growth factor-A.)
Sažetak
The aim of the present study was to evaluate angiogenesis by determining the micro vascular density (MVD) and the expression of vascular endothelial growth factor (VEGF-A) in advanced non-small cell lung cancer (NSCLC) tumor samples, and to analyze their associations with clinical parameters and survival. Tumor tissue specimens of fifty patients (41 males and 9 females), who underwent radical surgical treatment for NSCLC in stage IIIA (T1-3N2) were collected for immunohistochemical analysis. MVD evaluation was performed using an anti-CD31 monoclonal antibody and VEGF-A expression using a polyclonal anti-VEGF-A antibody. The results were associated with two-year survival. Statistical analysis revealed significant associations in the level of angiogenesis (high MVD) and shorter survival of patients with NSCLC (P=0.0007). VEGF-A expression showed no association with micro vascular density (P=0.51) or survival (P=0.68). There was no significant association between MVD and VEGF-A. The measurable, clinical MVD parameters could be used as a reliable prognostic factor for the survival of patients with advanced NSCLC.
Izvorni jezik
Engleski
POVEZANOST RADA
Profili:
Zvonko Zadro
(autor)
Ivan Bačić
(autor)
Ivan Bačić
(autor)
Anko Antabak
(autor)
Neven Skitarelić
(autor)
Robert Karlo
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus